Full Text of HR0103 103rd General Assembly
HR0103 103RD GENERAL ASSEMBLY |
| | HR0103 | | LRB103 31109 MST 57773 r |
|
| 1 | | HOUSE RESOLUTION
| 2 | | WHEREAS, The substance use and opioid use crises in | 3 | | Illinois are responsible for historically high rates of | 4 | | overdoses and overdose-related fatalities; and
| 5 | | WHEREAS, According to the State's own opioid data, use and | 6 | | misuse of opioids in Illinois also continues to have | 7 | | substantial associated public health consequences, including | 8 | | increased rates of infectious diseases such as hepatitis C and | 9 | | HIV, lost productivity in the workplace, crime, neonatal | 10 | | abstinence syndrome, and homelessness; and
| 11 | | WHEREAS, Substance use and opioid use are often | 12 | | detrimental to a person's mental health; access to innovative | 13 | | and evidence-based treatments that address substance use and | 14 | | opioid use can improve a patient's overall mental health; and | 15 | | WHEREAS, Historically disadvantaged groups face additional | 16 | | barriers to treatment for substance use and opioid use | 17 | | disorders, such as a lack of affordable therapy, stigma, and | 18 | | unequal access to mental health treatment; mental health | 19 | | equity should focus on access to quality and appropriate | 20 | | healthcare services; and | 21 | | WHEREAS, The purpose of many federal programs is to |
| | | HR0103 | - 2 - | LRB103 31109 MST 57773 r |
|
| 1 | | provide resources to states for increasing access to | 2 | | FDA-approved medications for the treatment of substance use | 3 | | and opioid use disorder and for supporting the continuum of | 4 | | prevention, harm reduction, treatment, and recovery support | 5 | | services for opioid use disorder and other substance use | 6 | | disorders; and
| 7 | | WHEREAS, A prescription digital therapeutic, which | 8 | | utilizes both cognitive behavioral therapy and contingency | 9 | | management in the product to treat substance use disorder or | 10 | | opioid use disorder, is approved, cleared, or classified by | 11 | | the Food and Drug Administration under section 510(k), 513(f), | 12 | | or 515 of the Federal Food, Drug, and Cosmetic Act and requires | 13 | | a prescription under section 801.109 of title 21 of the Code of | 14 | | Federal Regulations (or any successor regulation); and | 15 | | WHEREAS, Prescription digital therapeutics have the | 16 | | potential to significantly improve health care delivery to | 17 | | underserved populations because they transcend care access | 18 | | limitations due to geography, socioeconomic status, trust of | 19 | | traditional institutions, and more; and | 20 | | WHEREAS, Clinical studies have shown significantly greater | 21 | | odds of stimulant and opioid abstinence during treatment if | 22 | | treatment as usual is combined with an FDA-authorized PDT that | 23 | | has both cognitive behavioral therapy and contingency |
| | | HR0103 | - 3 - | LRB103 31109 MST 57773 r |
|
| 1 | | management; and | 2 | | WHEREAS, A 2018 study demonstrated that when a Community | 3 | | Reinforcement Approach and Contingency Management are | 4 | | administered together then a patient is 2.84 times more likely | 5 | | to remain abstinent at the end of the treatment than those in | 6 | | other programs; and
| 7 | | WHEREAS, The White House's Office of National Drug Control | 8 | | Policy recently released its 2022 National Drug Control | 9 | | Strategy document; specifically, the document points to | 10 | | prescription digital therapeutics and how these tools could | 11 | | help increase services for a wide array of patients; and
| 12 | | WHEREAS, Federally-funded programs help many states to | 13 | | fund access to FDA-authorized PDTs for patients and providers; | 14 | | therefore, be it
| 15 | | RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE | 16 | | HUNDRED THIRD GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that | 17 | | we urge the Department of Human Services and the Governor's | 18 | | Opioid Overdose Prevention and Recovery Steering Committee to | 19 | | closely consider funding FDA-authorized PDTs to help patients | 20 | | who are struggling with substance use and opioid use | 21 | | disorders; and be it further
|
| | | HR0103 | - 4 - | LRB103 31109 MST 57773 r |
|
| 1 | | RESOLVED, That a suitable copy of this resolution be | 2 | | delivered to the Secretary of the Illinois Department of Human | 3 | | Services.
|
|